Merck Licenses Cubicin For Japan
This article was originally published in The Pink Sheet Daily
Executive Summary
Deal completes global licensing of the first-in-class lipopeptide antibiotic for Cubist, which could collect over $45 million from Merck subsidiary Banyu.